Get the facts on cost and buprenorphine, how generics compare with brand names, what financial assistance may be available, and more.

The Suboxone Education Programme is a risk management programme that is founded on the following four core components that provide for the safe and effective use of the drug within a framework of ...

Introduction Buprenorphine is a highly effective treatment for opioid use disorder (OUD). However, provider observations and preliminary research suggest that the current standard maintenance dose may ...

At baseline, participants presented with opioid withdrawal and were assigned to daily sublingual buprenorphine-naloxone tablets or weekly ER, SC buprenorphine injections for 12 weeks.

Consider these observations in clinical decisions when prescribing buprenorphine and naloxone sublingual tablets to patients with QT-related risk factors.

Background Prior to approval in the European Union, a systematic benefit-risk assessment was required to compare buprenorphine implant to sublingual buprenorphine as part of the license application to ...

Suboxone launched in 2002 as a tablet, but lawyers have filed lawsuits over a sublingual film version that the U.S. Food and Drug Administration approved in 2010. More than a dozen lawsuits say ...

Medicare plans are replacing brand-name buprenorphine-naloxone film with its generic equivalents, resulting in a decrease in out-of-pocket cost faced by enrollees with opioid use disorder.

The lawsuit accused Indivior of attempting to head off generic competition and maintain its monopoly by using illegal means to switch patients from Suboxone tablets to a new, patented Suboxone ...

In 2010 — a year after Indivior's exclusive right to the Suboxone tablet expired and generics were set to compete — the company switched from tablet to sublingual film, alleging safety concerns.